RareSearch logo

BioLamina

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Wade Predovic-Franey profile

Wade Predovic-Franey

🇮🇩 Indonesia

8.9

    Reviewed:

  • - Regulatory Submission
  • - 6 weeks February 2023
  • - Biotech Startup

Professional and knowledgeable, seamless regulatory submission process.

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.

Jessie Jakubowski profile

Jessie Jakubowski

🇰🇷 South Korea

9.5

    Reviewed:

  • - Gene Therapy Development
  • - 12 weeks January - March 2023
  • - Research Institution

Innovative approach to gene therapy development, collaborative team.

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Ms. Emma Mertz profile

Ms. Emma Mertz

🇮🇳 India

6.5

    Reviewed:

  • - Regulatory Submission
  • - 8 weeks May - July 2024
  • - Pharmaceutical Company

Regulatory submission was incomplete, required additional work.

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Alex Toy profile

Alex Toy

🇩🇪 Germany

8.8

    Reviewed:

  • - Biostatistical Design
  • - 4 weeks May - June 2023
  • - Research Institution

Excellent biostatistical support, clear and actionable insights.

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.

Sylvester Dooley III profile

Sylvester Dooley III

🇸🇦 Saudi Arabia

6.3

    Reviewed:

  • - Stability Studies
  • - 16 months July 2023 - November 2024
  • - Pharmaceutical Company

Stability studies lacked detail, required additional validation.

The stability studies conducted were lacking in detail, and we had to perform additional validation to ensure the results were reliable. This added extra time and cost to the project. The team was responsive to feedback, but the initial work was subpar.

Ruben Schmitt III profile

Ruben Schmitt III

🇺🇸 United States

9.3

    Reviewed:

  • - Market Access Strategy
  • - 6 weeks January - February 2024
  • - Pharmaceutical Company

Strategic market access analysis, insightful recommendations.

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Walter Lowe profile

Walter Lowe

🇨🇳 China

8.9

    Reviewed:

  • - Stability Studies
  • - 18 months January 2023 - June 2024
  • - Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.